Literature DB >> 22892554

Donor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies.

Stefan O Ciurea1, Richard E Champlin.   

Abstract

Multiple donors are generally available for haploidentical hematopoietic stem cell transplantation. Here we discuss the factors that should be considered when selecting donors for this type of transplantation according to the currently available evidence. Donor-specific anti-HLA antibodies (DSAs) increase the risk of graft failure and should be avoided whenever possible. Strategies to manage recipients with DSAs are discussed. One should choose a full haplotype mismatch rather than a better-matched donor and maximize the dose of infused hematopoietic cells. Donor age and sex are other important factors. Other factors, including predicted natural killer cell alloreactivity and consideration of noninherited maternal alleles, are more controversial. Larger studies are needed to further clarify the role of these factors for donor selection in haploidentical hematopoietic stem cell transplantation.
Copyright © 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22892554      PMCID: PMC4085130          DOI: 10.1016/j.bbmt.2012.08.007

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  40 in total

1.  Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients.

Authors:  Hong Xu; Paula M Chilton; Michael K Tanner; Yiming Huang; Carrie L Schanie; Mariano Dy-Liacco; Jun Yan; Suzanne T Ildstad
Journal:  Blood       Date:  2006-08-03       Impact factor: 22.113

2.  Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age.

Authors:  C Kollman; C W Howe; C Anasetti; J H Antin; S M Davies; A H Filipovich; J Hegland; N Kamani; N A Kernan; R King; V Ratanatharathorn; D Weisdorf; D L Confer
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

3.  Superior survival of blood and marrow stem cell recipients given maternal grafts over recipients given paternal grafts.

Authors:  S Tamaki; T Ichinohe; K Matsuo; N Hamajima; N Hirabayashi; H Dohy
Journal:  Bone Marrow Transplant       Date:  2001-08       Impact factor: 5.483

4.  Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.

Authors:  Heather J Symons; M Sue Leffell; Nancy D Rossiter; Marianna Zahurak; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-02       Impact factor: 5.742

Review 5.  A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation.

Authors:  James L Gajewski; Viviana V Johnson; S Gerald Sandler; Antoine Sayegh; Thomas R Klumpp
Journal:  Blood       Date:  2008-06-26       Impact factor: 22.113

6.  Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome.

Authors:  Yvette L Kasamon; Leo Luznik; Mary S Leffell; Jeanne Kowalski; Hua-Ling Tsai; Javier Bolaños-Meade; Lawrence E Morris; Pamela A Crilley; Paul V O'Donnell; Nancy Rossiter; Carol Ann Huff; Robert A Brodsky; William H Matsui; Lode J Swinnen; Ivan Borrello; Jonathan D Powell; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2010-01-18       Impact factor: 5.742

7.  NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation.

Authors:  Loredana Ruggeri; Antonella Mancusi; Emanuela Burchielli; Marusca Capanni; Alessandra Carotti; Teresa Aloisi; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Blood Cells Mol Dis       Date:  2007-10-26       Impact factor: 3.039

8.  Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor.

Authors:  Martin Stern; Loredana Ruggeri; Antonella Mancusi; Maria Ester Bernardo; Claudia de Angelis; Christoph Bucher; Franco Locatelli; Franco Aversa; Andrea Velardi
Journal:  Blood       Date:  2008-05-20       Impact factor: 22.113

9.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Authors:  Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

10.  High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation.

Authors:  Stefan O Ciurea; Marcos de Lima; Pedro Cano; Martin Korbling; Sergio Giralt; Elizabeth J Shpall; Xuemei Wang; Peter F Thall; Richard E Champlin; Marcelo Fernandez-Vina
Journal:  Transplantation       Date:  2009-10-27       Impact factor: 4.939

View more
  19 in total

Review 1.  Haploidentical hematopoietic transplantation without T-cell depletion: current status and future perspectives.

Authors:  Lei Gao; Xi Zhang
Journal:  Stem Cell Investig       Date:  2015-10-20

Review 2.  Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy.

Authors:  Piyanuch Kongtim; Dean A Lee; Laurence J N Cooper; Partow Kebriaei; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-11       Impact factor: 5.742

Review 3.  Haploidentical hematopoietic stem cell transplantation: state of art.

Authors:  Y Reisner; F Aversa; M F Martelli
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

4.  Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation.

Authors:  Sameh Gaballa; Isabell Ge; Riad El Fakih; Jonathan E Brammer; Piyanuch Kongtim; Ciprian Tomuleasa; Sa A Wang; Dean Lee; Demetrios Petropoulos; Kai Cao; Gabriela Rondon; Julianne Chen; Aimee Hammerstrom; Lindsey Lombardi; Gheath Alatrash; Martin Korbling; Betul Oran; Partow Kebriaei; Sairah Ahmed; Nina Shah; Katayoun Rezvani; David Marin; Qaiser Bashir; Amin Alousi; Yago Nieto; Muzaffar Qazilbash; Chitra Hosing; Uday Popat; Elizabeth J Shpall; Issa Khouri; Richard E Champlin; Stefan O Ciurea
Journal:  Cancer       Date:  2016-07-12       Impact factor: 6.860

5.  Related haploidentical donors are a better choice than matched unrelated donors: Counterpoint.

Authors:  Bronwen E Shaw
Journal:  Blood Adv       Date:  2017-02-14

Review 6.  Donor HLA-specific Abs: to BMT or not to BMT?

Authors:  M S Leffell; R J Jones; D E Gladstone
Journal:  Bone Marrow Transplant       Date:  2015-02-23       Impact factor: 5.483

7.  EBMT risk score can predict the outcome of leukaemia after unmanipulated haploidentical blood and marrow transplantation.

Authors:  H-T Wang; Y-J Chang; L-P Xu; D-H Liu; Y Wang; K-Y Liu; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

8.  Transplacental maternal engraftment and posttransplantation graft-versus-host disease in children with severe combined immunodeficiency.

Authors:  Justin Wahlstrom; Kiran Patel; Erik Eckhert; Denice Kong; Biljana Horn; Morton J Cowan; Christopher C Dvorak
Journal:  J Allergy Clin Immunol       Date:  2016-06-16       Impact factor: 10.793

9.  Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation.

Authors:  Monzr M Al Malki; Dongyun Yang; Myriam Labopin; Boris Afanasyev; Emanuele Angelucci; Asad Bashey; Gérard Socié; Amado Karduss-Urueta; Grzegorz Helbig; Martin Bornhauser; Riitta Niittyvuopio; Arnold Ganser; Fabio Ciceri; Arne Brecht; Yener Koc; Nelli Bejanyan; Francesca Ferraro; Partow Kebriaei; Sally Mokhtari; Armin Ghobadi; Ryotaro Nakamura; Stephen J Forman; Richard Champlin; Mohamad Mohty; Stefan O Ciurea; Arnon Nagler
Journal:  Blood Adv       Date:  2020-05-12

Review 10.  Haploidentical Donor Bone Marrow Transplantation for Severe Aplastic Anemia.

Authors:  Amy E DeZern; Robert A Brodsky
Journal:  Hematol Oncol Clin North Am       Date:  2018-05-28       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.